Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

6(100.0%)

6Total

N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07360977Not ApplicableRecruiting

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

Role: collaborator

NCT03568409Not ApplicableCompleted

ABO-GLYC in Type 2 Diabetes

Role: collaborator

NCT05231317Not ApplicableCompleted

Effect of the Sustainable Diet on Gut Microbiota and the Metabolome: a Randomised Crossover Study

Role: collaborator

NCT03369548Not ApplicableUnknown

CABALA Diet & Health Study

Role: collaborator

NCT02664428Not ApplicableCompleted

Measuring the Impact of Dietary Supplementation With a New Baking Product on Gut Microbiota and Cholesterol Metabolism

Role: lead

NCT02067026Not ApplicableCompleted

Measuring the Impact of Dietary Supplementation With a High Fiber, High Antioxidant Aleurone on Biomarkers of Cardiovascular Disease and Gut Microbiota in Adults With High Body Mass Index

Role: lead

All 6 trials loaded